Aligos Therapeutics, Inc. (ALGS)

Aligos Therapeutics, Inc. (ALGS) is a healthcare company (biotechnology) based in the United States. The share price is $1.44, down 13.25% on the day, which values the company at $9M. Price as of 17 Nov 2026, 17:26 UTC, from Yahoo Finance.

Key facts

Share price
$1.44−13.25% today
Market value
$9M
Funk Score
28/100
Against its own history
Well below its usual priceusual price $3.74
200-week average
$15.1390% below
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Aligos Therapeutics, Inc. in more detail

ALGS trades at -0.2× next year's expected earnings, 0.3× sales. Measured against its own history, the price is 62% below what its usual multiples would imply ($3.74) — well below its usual price. It sits 90% below its 200-week average of $15.13.

Its Funk Score is 28 out of 100 (financial strength 4.6, profitability 0.0, growth 1.7, value 5.0, each out of 10).

In its favour: More cash than debt. Worth checking: Altman Z in the distress zone; Weak Piotroski score.

2 of the superinvestors tracked here hold ALGS, including Zhang Lei (0.1% of the portfolio), Julian and Felix Baker (0.0% of the portfolio).

Superinvestors holding ALGS

2 of the investors tracked here report a position in their latest 13F filing.

Aligos Therapeutics, Inc. (ALGS): questions and answers

What is Aligos Therapeutics, Inc.'s market cap?

Aligos Therapeutics, Inc. is valued at $9M at a share price of $1.44.

Is ALGS overvalued or undervalued?

Against its own history, ALGS is well below its usual price: the price is 62% below the $3.74 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is ALGS above its 200-week moving average?

No. ALGS is 90.5% below its 200-week average of $15.13. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is Aligos Therapeutics, Inc. growing?

Over the last three fiscal years Aligos Therapeutics, Inc.'s revenue grew -46.0% a year.

Does ALGS pay a dividend?

Aligos Therapeutics, Inc. does not currently pay a regular dividend.

Which famous investors own ALGS?

In their latest quarterly filings, Zhang Lei (0.1% of the portfolio), Julian and Felix Baker (0.0% of the portfolio) hold ALGS. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

Cite this page

Funkfolio, “Aligos Therapeutics, Inc. (ALGS) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/ALGS

Underlying data: Yahoo Finance; company filings with the SEC.